Characterization_NN of_IN Sparsomycin_NP Resistance_NP in_IN Streptomyces_NP sparsogenes_NNS The_DT antitumor_NN antibiotic_NN sparsomycin_NN ,_, produced_VBN by_IN Streptomyces_NP sparsogenes_NNS ,_, is_VBZ a_DT universal_JJ translation_NN inhibitor_NN that_WDT blocks_VBZ the_DT peptide_NN bond_NN formation_NN in_IN ribosomes_NNS from_IN all_DT species_NN ._SENT Sparsomycin-resistant_JJ strains_NNS were_VBD selected_VBN by_IN transforming_VBG the_DT sensitive_JJ Streptomyces_NP lividans_NNS with_IN an_DT S._NP sparsogenes_NNS library_NN ._SENT Resistance_NN was_VBD linked_VBN to_TO the_DT presence_NN of_IN a_DT plasmid_NN containing_VBG an_DT S._NP sparsogenes_NNS 5.9-kbp_JJ DNA_NP insert_NN ._SENT A_DT restriction_NN analysis_NN of_IN the_DT insert_NN traced_VBD down_RP the_DT resistance_NN to_TO a_DT 3.6-kbp_JJ DNA_NN fragment_NN ,_, which_WDT was_VBD sequenced_JJ ._SENT The_DT analysis_NN of_IN the_DT fragment_NN nucleotide_NN sequence_NN together_RB with_IN the_DT previous_JJ restriction_NN data_NNS associate_VBP the_DT resistance_NN to_TO srd_NN ,_, an_DT open_JJ reading_NN frame_NN of_IN 1,800_CD nucleotides_NNS ._SENT Ribosomes_NNS from_IN S._NP sparsogenes_NNS and_CC the_DT S._NP lividans-resistant_NN strains_NNS are_VBP equally_RB sensitive_JJ to_TO the_DT inhibitor_NN and_CC bind_VB the_DT drug_NN with_IN similar_JJ affinity_NN ._SENT Moreover_RB ,_, the_DT drug_NN was_VBD not_RB modified_VBN by_IN the_DT resistant_JJ strains_NNS ._SENT However_RB ,_, resistant_JJ cells_NNS accumulated_VBN less_RBR antibiotic_JJ than_IN the_DT sensitive_JJ ones_NNS ._SENT In_IN addition_NN ,_, membrane_NN fractions_NNS from_IN the_DT resistant_JJ strains_NNS showed_VBD a_DT higher_JJR capacity_NN for_IN binding_VBG the_DT drug_NN ._SENT The_DT results_NNS indicate_VBP that_IN resistance_NN in_IN the_DT producer_NN strain_NN is_VBZ not_RB connected_VBN to_TO either_DT ribosome_NN modification_NN or_CC drug_NN inactivation_NN ,_, but_CC it_PP might_MD be_VB related_VBN to_TO an_DT alteration_NN in_IN the_DT sparsomycin_NN permeability_NN barrier_NN ._SENT The_DT antitumor_NN antibiotic_NN sparsomycin_NN is_VBZ a_DT universal_JJ translation_NN inhibitor_NN that_WDT blocks_VBZ protein_NN synthesis_NN in_IN all_DT species_NNS (_( for_IN a_DT review_NN ,_, see_VBP reference_NN )_) ._SENT The_DT broad_JJ spectrum_NN of_IN sparsomycin_NN action_NN indicated_VBD that_IN the_DT drug_NN was_VBD targeted_VBN to_TO a_DT highly_RB conserved_VBN component_NN of_IN the_DT translation_NN machinery_NN ._SENT The_DT relevance_NN of_IN the_DT target_NN was_VBD also_RB supported_VBN by_IN the_DT fact_NN that_IN mutations_NNS inducing_VBG high_JJ resistance_NN to_TO sparsomycin_NN have_VBP not_RB been_VBN reported_VBN ,_, and_CC only_RB a_DT moderately_RB resistant_JJ strain_NN has_VBZ been_VBN found_VBN in_IN Halobacterium_NP salinarium_NN ._SENT In_IN fact_NN ,_, it_PP was_VBD soon_RB shown_VBN that_IN sparsomycin_NN blocks_NNS the_DT peptide_NN bond_NN formation_NN ._SENT The_DT drug_NN binds_VBZ and_CC causes_VBZ important_JJ conformational_JJ changes_NNS in_IN the_DT peptidyl_NN transferase_NN active_JJ center_NN ._SENT Thus_RB ,_, it_PP was_VBD found_VBN that_IN sparsomycin_NN can_MD block_VB the_DT binding_NN of_IN substrates_NNS at_IN the_DT A-site_NN but_CC enhances_VBZ binding_VBG to_TO the_DT P-site_NN ._SENT Actually_RB ,_, sparsomycin_NN has_VBZ been_VBN a_DT very_RB powerful_JJ tool_NN in_IN the_DT study_NN of_IN the_DT structure_NN and_CC function_NN of_IN the_DT ribosome_NN ._SENT Recently_RB ,_, the_DT antibiotic_NN was_VBD found_VBN to_TO interact_VB with_IN nucleotide_NN A2602_NN in_IN the_DT peptidyl_NN transferase_NN center_NN of_IN the_DT bacterial_JJ ribosome_NN ._SENT The_DT drug_NN was_VBD initially_RB developed_VBN as_IN a_DT potential_JJ antitumor_NN agent_NN ,_, although_IN toxicity_NN soon_RB limited_VBN its_PP$ clinical_JJ application_NN ._SENT Nevertheless_RB ,_, the_DT synthesis_NN of_IN a_DT series_NN of_IN sparsomycin_NN derivatives_NNS with_IN higher_JJR inhibitory_JJ activities_NNS has_VBZ led_VBN to_TO a_DT reappraisal_NN of_IN its_PP$ potential_NN as_IN an_DT anticancer_NN drug_NN ._SENT Sparsomyin_NP is_VBZ produced_VBN by_IN Streptomyces_NP sparsogenes_NNS ,_, which_WDT is_VBZ obviously_RB resistant_JJ to_TO the_DT drug_NN ._SENT Organisms_NNS producing_VBG toxic_JJ compounds_NNS ,_, including_VBG antibiotics_NNS ,_, use_VBP different_JJ approaches_NNS to_TO defend_VB themselves_PP from_IN their_PP$ own_JJ action_NN ._SENT Not_RB the_DT least_JJS frequent_JJ approach_NN is_VBZ to_TO modify_VB the_DT target_NN ,_, making_VBG it_PP insensitive_JJ to_TO the_DT drug_NN ._SENT Thus_RB ,_, methylation_NN of_IN specific_JJ residues_NNS within_IN the_DT 16S_JJ rRNA_NN makes_VBZ the_DT ribosomes_NNS of_IN many_JJ aminoglycoside_NN antibiotic_NN producers_NNS resistant_JJ to_TO their_PP$ respective_JJ products_NNS ._SENT The_DT same_JJ strategy_NN is_VBZ used_VBN by_IN the_DT producers_NNS of_IN macrolides_NNS ,_, lincosamides_NNS ,_, pactamycin_NN ,_, and_CC thiostrepton_NN ._SENT The_DT study_NN of_IN these_DT resistance_NN mechanisms_NNS has_VBZ provided_VBN relevant_JJ information_NN on_IN the_DT antibiotic_JJ mode_NN of_IN action_NN and_CC on_IN the_DT ribosomal_JJ binding_JJ site_NN at_IN the_DT molecular_JJ level_NN ._SENT It_PP would_MD be_VB important_JJ ,_, therefore_RB ,_, to_TO see_VB whether_IN S._NP sparsogenes_NNS ,_, like_IN other_JJ antibiotic-producing_NN streptomycetes_NNS ,_, has_VBZ managed_VBN to_TO modify_VB the_DT highly_RB conserved_VBN sparsomycin_NN target_NN site_NN to_TO make_VB the_DT ribosomes_NNS resistant_JJ to_TO the_DT drug_NN ._SENT Alternatively_RB ,_, as_RB in_IN the_DT case_NN of_IN other_JJ producers_NNS ,_, a_DT different_JJ resistance_NN mechanism_NN ,_, such_JJ as_IN drug_NN inactivation_NN or_CC permeability_NN barrier_NN alterations_NNS ,_, might_MD have_VB evolved_VBN (_( for_IN a_DT review_NN ,_, see_VBP reference_NN )_) ,_, perhaps_RB because_IN modification_NN of_IN the_DT target_NN is_VBZ not_RB possible_JJ without_IN seriously_RB affecting_VBG its_PP$ activity_NN ._SENT We_PP have_VBP approached_VBN the_DT study_NN of_IN sparsomycin_NN resistance_NN by_IN directly_RB analyzing_VBG the_DT producer_NN and_CC by_IN trying_VBG to_TO characterize_VB genetic_JJ determinants_NNS from_IN S._NP sparsogenes_NNS that_WDT provide_VBP resistance_NN in_IN Streptomyces_NP lividans_NNS ,_, an_DT organism_NN susceptible_JJ to_TO the_DT drug_NN ._SENT Bacterial_JJ strains_NNS and_CC culture_NN media_NNS ._SENT |_SYM Streptomyces_NP strains_NNS were_VBD S._NP sparsogenes_NP ISP5356_NP (_( ATCC_NP 25498_CD )_) ,_, S._NP lividans_NNS 1326_CD ,_, and_CC S._NP lividans_NNS 3131_CD ,_, which_WDT corresponds_VBZ to_TO S._NP lividans_NNS 1326_CD transformed_VBN with_IN plasmid_NP pIJ702_NN ._SENT Streptomyces_NP spp._NP were_VBD grown_VBN in_IN yeast_NN extract-malt_NN extract_NN (_( YEME_NP )_) liquid_JJ medium_NN or_CC on_IN R5_NP agar_NN plates_NNS ._SENT R2YE_NN plates_NNS were_VBD used_VBN for_IN the_DT regeneration_NN of_IN protoplasts_NNS after_IN transformation_NN ._SENT Escherichia_NP coli_NNS DH5alpha_NP was_VBD used_VBN for_IN manipulating_VBG plasmids_NNS ._SENT Growth_NN conditions_NNS for_IN E._NP coli_NNS were_VBD as_RB described_VBN elsewhere_RB ._SENT Sensitivity_NN of_IN Streptomyces_NP spp._NP to_TO antibiotics_NNS ._SENT |_SYM The_DT sensitivities_NNS of_IN the_DT different_JJ strains_NNS of_IN Streptomyces_NP spp._NP to_TO antibiotics_NNS were_VBD assayed_VBN either_RB in_IN liquid_JJ medium_NN (_( YEME_NP )_) or_CC on_IN R5_NP plates_NNS containing_VBG the_DT amount_NN of_IN antibiotic_NN indicated_VBD below_RB ._SENT Inhibition_NN in_IN liquid_JJ medium_NN was_VBD estimated_VBN by_IN monitoring_VBG the_DT A550_NP of_IN the_DT cultures_NNS ._SENT Inhibition_NN on_IN agar_NN plates_NNS was_VBD determined_VBN either_RB by_IN colony_NN counting_NN or_CC by_IN the_DT size_NN of_IN the_DT halo_NN formed_VBN in_IN the_DT plate_NN around_IN 3-mm-diameter_JJ paper_NN disks_NNS containing_VBG the_DT antibiotics_NNS at_IN the_DT indicated_JJ concentrations_NNS ._SENT Unless_IN otherwise_RB indicated_VBN ,_, thiostrepton_NN was_VBD not_RB included_VBN in_IN the_DT media_NNS ,_, to_TO avoid_VB possible_JJ effects_NNS on_IN antibiotic_JJ resistance_NN ._SENT DNA_NP manipulation_NN ._SENT |_SYM Restriction_NP enzyme_NN digestions_NNS ,_, ligations_NNS ,_, agarose_JJ gel_NN electrophoresis_NN ,_, etc._FW ,_, were_VBD performed_VBN according_VBG to_TO well-established_JJ techniques_NNS ._SENT Restriction_NN endonucleases_NNS were_VBD purchased_VBN from_IN Boehringer_NP Mannheim_NP ,_, MBI_NP Fermentas_NP ,_, New_NP England_NP Biolabs_NP ,_, and_CC Amersham_NP and_CC were_VBD used_VBN as_IN recommended_VBN by_IN the_DT suppliers_NNS ._SENT T4_NP DNA_NP ligase_NN ,_, calf_NN intestinal_JJ alkaline_JJ phosphatase_NN ,_, and_CC the_DT DNA_NP polymerase_NN I_NP Klenow_NP fragment_NN were_VBD from_IN Boehringer_NP Mannheim_NP ._SENT Standard_JJ procedures_NNS were_VBD used_VBN for_IN propagation_NN and_CC subcloning_NN of_IN plasmids_NNS in_IN E._NP coli_NNS ._SENT Nucleotide_NN sequences_NNS of_IN DNA_NN inserts_NNS were_VBD determined_VBN on_IN both_DT strands_NNS using_VBG a_DT Dye-Terminator_NN cycle_NN sequencing_VBG ready_JJ reaction_NN kit_NN (_( Applied_NP Biosystems_NP )_) with_IN custom-made_JJ oligonucleotides_NNS as_IN primers_NNS ._SENT Sequencing_NP reactions_NNS were_VBD run_VBN on_IN an_DT automated_JJ DNA_NN sequencer_NN (_( model_NN 377_CD ;_: Applied_NP Biosystems_NP )_) ._SENT Preparation_NN and_CC screening_NN of_IN a_DT genomic_JJ library_NN of_IN S._NP sparsogenes_NNS ._SENT |_SYM Genomic_NP DNA_NP from_IN S._NP sparsogenes_NNS (_( 60_CD mug_NN )_) ,_, prepared_VBN according_VBG to_TO the_DT methods_NNS described_VBN in_IN reference_NN ,_, was_VBD partially_RB digested_VBN with_IN Sau3A_NP (_( 0.03_CD U_NN of_IN enzyme_NN per_IN mug_NN of_IN DNA_NP ;_: 15_CD min_NN at_IN 37C_JJ )_) ._SENT Six-_NN to_TO 8-kbp_JJ fragments_NNS were_VBD purified_VBN by_IN agarose_JJ gel_NN electrophoresis_NN ,_, and_CC 10_CD mug_NN of_IN the_DT sample_NN was_VBD ligated_VBN to_TO 2_CD mug_NN of_IN pIJ702_NN obtained_VBN from_IN S._NP lividans_NNS 3131_CD and_CC purified_VBN by_IN cesium_NN chloride-ethidium_NN bromide_NN gradient_JJ centrifugation_NN ._SENT The_DT plasmid_NN was_VBD previously_RB digested_VBN with_IN BglII_NP and_CC treated_VBN with_IN alkaline_JJ phosphatase_NN to_TO prevent_VB recircularization_NN ._SENT The_DT ligation_NN mixture_NN was_VBD used_VBN to_TO transform_VB S._NP lividans_NNS 1326_CD protoplasts_NNS according_VBG to_TO standard_JJ techniques_NNS ._SENT The_DT screening_NN of_IN the_DT library_NN was_VBD done_VBN in_IN two_CD steps_NNS ._SENT First_RB ,_, the_DT transformants_NNS were_VBD tested_VBN for_IN a_DT plasmid_NP marker_NN (_( resistance_NN to_TO the_DT antibiotic_JJ thiostrepton_NN )_) ._SENT The_DT thiostrepton-resistant_NN colonies_NNS ,_, numbering_VBG approximately_RB 5,000_CD ,_, were_VBD allowed_VBN to_TO sporulate_VB and_CC the_DT spores_NNS were_VBD tested_VBN for_IN resistance_NN to_TO sparsomycin_NN on_IN plates_NNS containing_VBG 100_CD mug_NN of_IN the_DT antibiotic/ml_NN but_CC in_IN the_DT absence_NN of_IN thiostrepton_NN ,_, which_WDT has_VBZ been_VBN reported_VBN to_TO affect_VB the_DT sensitivity_NN of_IN S._NP lividans_NNS to_TO different_JJ translation_NN inhibitors_NNS ,_, including_VBG sparsomycin_NN ._SENT Preparation_NN of_IN cell_NN extracts_VBZ and_CC ribosomes_NNS ._SENT |_SYM Total_JJ cell_NN extracts_VBZ (_( S30_NP and_CC S100_NP fractions_NNS )_) and_CC ribosomes_NNS from_IN the_DT different_JJ Streptomyces_NP strains_NNS were_VBD prepared_VBN as_IN previously_RB described_VBN ._SENT Activity_NN tests_NNS ._SENT |_SYM (_( i_NP )_) Binding_NP of_IN 125I-labeled_JJ phenol-sparsomycin_NN to_TO ribosomes_NNS ._SENT Ribosomes_NNS (_( 1.0_CD muM_NN )_) were_VBD incubated_VBN for_IN 30_CD min_NN at_IN 30C_JJ with_IN increasing_VBG amounts_NNS of_IN 125I-labeled_JJ phenol-sparsomycin_NN (_( 0.1_CD muM_NN ;_: 103_CD cpm/pmol_NN )_) in_IN 50_CD mul_NN of_IN binding_JJ buffer_NN (_( 10_CD mM_NP Tris-HCl_NP ,_, 10_CD mM_NP MgCl2_NP ,_, 60_CD mM_NP NH4Cl_NP ,_, 6_CD mM_NP beta-mercaptoethanol_NN )_) ._SENT After_IN incubation_NN the_DT samples_NNS were_VBD diluted_VBN with_IN 5_CD ml_NN of_IN binding_JJ buffer_NN and_CC filtered_VBN through_IN nitrocellulose_NN filters_NNS ._SENT After_IN two_CD washes_VBZ with_IN the_DT same_JJ buffer_NN ,_, filters_NNS were_VBD counted_VBN in_IN a_DT gamma_NN counter_NN to_TO estimate_VB the_DT amount_NN of_IN drug_NN bound_VBN to_TO ribosomes_NNS ._SENT (_( ii_NP )_) Polyphenylalanine_NP synthesis_NN ._SENT |_SYM The_DT polymerizing_VBG activity_NN of_IN the_DT Streptomyces_NP extracts_VBZ was_VBD estimated_VBN by_IN a_DT poly(U)-dependent_JJ polyphenylalanine_NN synthesis_NN assay_NN carried_VBD out_RP as_RB described_VBN elsewhere_RB ._SENT Analysis_NN of_IN in_IN vivo_JJ sparsomycin_NN modification_NN ._SENT |_SYM S._NP sparsogenes_NP and_CC S._NP lividans_NNS cells_NNS were_VBD grown_VBN to_TO mid-exponential_JJ phase_NN ._SENT Cells_NNS were_VBD collected_VBN by_IN centrifugation_NN (_( 10_CD min_NN at_IN 10,000_CD rpm_NN in_IN an_DT SS-34_NP rotor_NN )_) and_CC resuspended_JJ in_IN binding_VBG buffer_NN to_TO an_DT A550_NP of_IN 5_CD ._SENT A_DT 200-mul_JJ aliquot_NN of_IN the_DT suspension_NN of_IN cells_NNS was_VBD incubated_VBN with_IN 100,000_CD cpm_NN of_IN 0.1_CD muM_NN 125I-labeled_JJ phenol-alanine-sparsomycin_NN (_( 104_CD cpm/pmol_NN )_) for_IN 1_CD h_NN at_IN 30C_JJ ._SENT Cells_NNS were_VBD recovered_VBN by_IN centrifugation_NN ,_, resuspended_VBN again_RB in_IN 200_CD mul_NN of_IN binding_JJ buffer_NN ,_, and_CC broken_VBN ._SENT The_DT antibiotic_NN was_VBD extracted_VBN from_IN both_DT pellet_NN and_CC supernatant_JJ fractions_NNS by_IN mixing_VBG them_PP with_IN an_DT equal_JJ volume_NN of_IN ethyl_NN acetate_NN ,_, and_CC the_DT organic_JJ and_CC the_DT aqueous_JJ phases_NNS were_VBD separated_VBN by_IN centrifugation_NN ._SENT The_DT organic_JJ phase_NN was_VBD collected_VBN and_CC concentrated_VBN by_IN evaporation_NN ._SENT The_DT radioactive_JJ antibiotic_NN was_VBD analyzed_VBN by_IN thin-layer_JJ chromatography_NN on_IN precoated_JJ silica_NN gel_NN plates_NNS ,_, using_VBG chloroform-methanol_NN (_( 80:20_CD or_CC 80:10_CD )_) as_IN a_DT solvent_NN ._SENT Accumulation_NN of_IN sparsomycin_NN by_IN the_DT cells_NNS ._SENT |_SYM Streptomyces_NP cells_NNS were_VBD grown_VBN until_IN the_DT A550_NP reached_VBD 0.2_CD ._SENT Cells_NNS from_IN 100_CD ml_NN of_IN medium_NN were_VBD collected_VBN by_IN centrifugation_NN and_CC resuspended_JJ in_IN 4_CD ml_NN of_IN binding_JJ buffer_NN ,_, and_CC 100_CD mul_NN of_IN the_DT suspension_NN was_VBD incubated_VBN with_IN 100,000_CD cpm_NN of_IN 125I-labeled_JJ phenol-alanine-sparsomycin_NN (_( 104_CD cpm/pmol_NN )_) for_IN different_JJ periods_NNS ._SENT After_IN the_DT incubation_NN ,_, the_DT cells_NNS were_VBD diluted_VBN with_IN 5_CD ml_NN of_IN binding_JJ buffer_NN and_CC filtered_VBN through_IN glass_NN fiber_NN filters_NNS ._SENT The_DT filters_NNS were_VBD washed_VBN two_CD times_NNS with_IN 5_CD ml_NN of_IN the_DT same_JJ buffer_NN and_CC dried_VBD ,_, and_CC the_DT radioactivity_NN was_VBD estimated_VBN by_IN scintillation_NN counting_NN ._SENT Binding_VBG of_IN radioactive_JJ sparsomycin_NN to_TO subcellular_JJ fractions_NNS ._SENT |_SYM The_DT different_JJ Streptomyces_NP strains_NNS were_VBD grown_VBN in_IN 50_CD ml_NN of_IN medium_NN to_TO an_DT A550_NP of_IN 0.2_CD ,_, collected_VBN by_IN centrifugation_NN ,_, washed_VBN with_IN binding_JJ buffer_NN ,_, and_CC resuspended_VBD in_IN the_DT same_JJ buffer_NN to_TO an_DT A550_NP of_IN 5.0_CD ._SENT Cells_NNS were_VBD broken_VBN in_IN a_DT French_JJ press_NN ,_, and_CC the_DT extracts_VBZ were_VBD centrifuged_VBN at_IN 15,000_CD x_NN g_NN for_IN 30_CD min_NN to_TO obtain_VB a_DT membrane_NN fraction_NN ._SENT Ribosomes_NNS were_VBD prepared_VBN by_IN centrifuging_VBG the_DT supernatant_JJ at_IN 100,000_CD x_NN g_NN for_IN 3_CD h._JJ Aliquots_NNS containing_VBG equivalent_JJ amounts_NNS of_IN the_DT different_JJ fractions_NNS were_VBD incubated_VBN with_IN 100,000_CD cpm_NN of_IN 125I-labeled_JJ phenol-alanine-sparsomycin_NN (_( 103_CD cpm/pmol_NN )_) for_IN 30_CD min_NN at_IN 30C_JJ ._SENT The_DT bound_JJ drug_NN was_VBD estimated_VBN as_IN described_VBN previously_RB ._SENT Nucleotide_NN sequence_NN accession_NN number_NN ._SENT |_SYM The_DT sequence_NN of_IN the_DT S._NP sparsogenes_NP DNA_NP fragment_NN reported_VBD here_RB was_VBD submitted_VBN to_TO the_DT EMBL_NP nucleotide_NN sequence_NN database_NN and_CC assigned_VBN the_DT accession_NN number_NN ._SENT Isolation_NN of_IN S._NP lividans_NNS sparsomycin-resistant_NN strains_NNS ._SENT |_SYM S._NP lividans_NNS was_VBD transformed_VBN with_IN an_DT S._NP sparsogenes_NNS genomic_JJ DNA_NP library_NN in_IN plasmid_NP pIJ702_NN and_CC prepared_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Seven_CD transformants_NNS were_VBD initially_RB selected_VBN which_WDT were_VBD able_JJ to_TO grow_VB on_IN agar_NN plates_NNS containing_VBG 100_CD mug_NN of_IN sparsomycin/ml_NN ._SENT The_DT parental_JJ S._NP lividans_NNS was_VBD totally_RB inhibited_VBN with_IN 20_CD mug_NN of_IN drug/ml_NN under_IN similar_JJ growing_VBG conditions_NNS ._SENT When_WRB spores_NNS were_VBD prepared_VBN from_IN resistant_JJ clones_NNS and_CC allowed_VBN to_TO grow_VB again_RB in_IN the_DT presence_NN of_IN sparsomycin_NN ,_, only_RB one_CD of_IN them_PP ,_, SLT4_NP ,_, showed_VBD the_DT same_JJ resistant_JJ phenotype_NN ,_, as_RB well_RB as_IN conserving_VBG the_DT thiostrepton_NN resistance_NN marker_NN of_IN the_DT pIJ702_JJ vector_NN ._SENT S._NP lividans_NNS transformed_VBN with_IN the_DT empty_JJ pJI702_NN did_VBD not_RB show_VB any_DT resistance_NN to_TO the_DT drug_NN in_IN the_DT absence_NN of_IN thiostrepton_NN ._SENT The_DT resistance_NN of_IN SLT4_NP to_TO sparsomycin_NN is_VBZ associated_VBN with_IN the_DT presence_NN of_IN the_DT transforming_VBG construct_NN containing_VBG S._NP sparsogenes_NNS DNA_NN ,_, since_IN curing_VBG the_DT plasmid_NN ,_, which_WDT resulted_VBD in_IN a_DT loss_NN of_IN thiostrepton_NN resistance_NN ,_, caused_VBD a_DT concomitant_JJ loss_NN of_IN the_DT sparsomycin_NN resistance_NN phenotype_NN ._SENT Unexpectedly_RB ,_, the_DT sparsomycin-resistant_JJ strain_NN showed_VBD alterations_NNS in_IN sensitivity_NN to_TO other_JJ protein_NN synthesis_NN inhibitors_NNS ._SENT Thus_RB ,_, S._NP lividans_NP SLT4_NP shows_VBZ a_DT notable_JJ increase_NN in_IN its_PP$ sensitivity_NN to_TO chloramphenicol_NN and_CC tetracycline_NN while_IN having_VBG a_DT higher_JJR resistance_NN to_TO lincomycin_NN and_CC puromycin_NN ._SENT Characterization_NN of_IN the_DT resistance_NN determinant_NN ._SENT |_SYM The_DT plasmid_NN present_NN in_IN S._NP lividans_NP SLT4_NP was_VBD isolated_VBN and_CC characterized_VBN ._SENT A_DT DNA_NP insert_NN of_IN 5.9-kbp_NP was_VBD found_VBN ,_, which_WDT was_VBD fragmented_VBN using_VBG appropriate_JJ restriction_NN sites_NNS ;_: the_DT fragments_NNS were_VBD subcloned_VBN in_IN the_DT same_JJ plasmid_NN ,_, pIJ702_NN ._SENT The_DT new_JJ plasmids_NNS were_VBD used_VBN to_TO transform_VB S._NP lividans_NNS 1326_CD ,_, and_CC the_DT transformants_NNS were_VBD tested_VBN for_IN resistance_NN to_TO sparsomycin_NN ._SENT In_IN this_DT way_NN ,_, a_DT minimal_JJ fragment_NN of_IN 3.6_CD kbp_NN (_( Fig._NN ,_, insert_NN 3_CD )_) was_VBD found_VBN to_TO be_VB able_JJ to_TO induce_VB resistance_NN to_TO the_DT drug_NN ._SENT None_NN of_IN the_DT S._NP sparsogenes_NNS DNA_NN fragments_NNS subcloned_VBN in_IN a_DT pBluescript_NN plasmid_NN were_VBD able_JJ to_TO provide_VB sparsomycin_NN resistance_NN in_IN E._NP coli_NNS ._SENT The_DT fragment_NN was_VBD sequenced_JJ ,_, and_CC the_DT analysis_NN of_IN the_DT sequence_NN indicated_VBD the_DT presence_NN of_IN two_CD ORFs_NNS (_( srd_NN and_CC moxR_NN )_) and_CC a_DT fragment_NN of_IN a_DT third_JJ ORF_NP encoding_VBG a_DT transmembrane_NN polypeptide_NN (_( tmp_NN )_) at_IN one_CD of_IN the_DT ends_NNS ._SENT Restriction_NN analysis_NN and_CC subcloning_VBG of_IN the_DT original_JJ fragment_NN (_( Fig._NN ,_, insert_NN 1_CD )_) indicated_VBD that_DT insert_NN 4_CD ,_, comprising_VBG the_DT middle_JJ ORF_NP --_: -which_NP showed_VBD homology_NN to_TO moxR_NN --_: -and_NN the_DT incomplete_JJ tmp_NN ORF_NP did_VBD not_RB induce_VB resistance_NN ._SENT In_IN addition_NN ,_, disruption_NN of_IN srd_NN by_IN cutting_VBG insert_NN 3_CD to_TO obtain_VB inserts_NNS 4_CD and_CC 5_CD resulted_VBN in_IN loss_NN of_IN resistance_NN ._SENT It_PP seems_VBZ ,_, therefore_RB ,_, that_IN the_DT sparsomycin_NN resistance_NN determinant_NN ,_, srd_NN ,_, must_MD be_VB associated_VBN with_IN the_DT first_JJ ORF_NP in_IN the_DT sequenced_JJ fragment_NN ._SENT The_DT srd_NP ORF_NP carries_VBZ GTG_NP as_IN a_DT putative_JJ initiator_NN codon_NN and_CC seven_CD nucleotides_NNS at_IN the_DT 5_CD '_POS end_NN of_IN the_DT fragment_NN ._SENT It_PP is_VBZ probably_RB expressed_VBN from_IN a_DT promoter_NN in_IN the_DT vector_NN and_CC encodes_VBZ a_DT 601-amino-acid-long_JJ polypeptide_NN ._SENT No_DT significant_JJ homology_NN of_IN this_DT S._NP sparsogenes_NNS DNA_NN to_TO any_DT sequence_NN in_IN the_DT data_NNS bank_NN could_MD be_VB found_VBN ._SENT Similarly_RB ,_, no_DT relevant_JJ standard_JJ functional_JJ or_CC structural_JJ domain_NN was_VBD detected_VBN in_IN the_DT polypeptide_NN sequence_NN ,_, except_IN for_IN one_CD weak_JJ transmembrane_NN domain_NN ._SENT Biochemical_JJ characterization_NN of_IN the_DT resistance_NN mechanism_NN ._SENT |_SYM Three_CD main_JJ resistance_NN mechanisms_NNS are_VBP usually_RB responsible_JJ for_IN the_DT resistance_NN of_IN cells_NNS to_TO drugs_NNS :_: (_( i_NP )_) reduction_NN of_IN the_DT target_NN affinity_NN for_IN the_DT drug_NN ;_: (_( ii_NP )_) inactivation_NN of_IN the_DT drug_NN ;_: and_CC (_( iii_NN )_) alteration_NN of_IN the_DT permeability_NN barrier_NN affecting_VBG the_DT transport_NN ._SENT In_IN the_DT first_JJ case_NN ,_, the_DT reduction_NN of_IN the_DT affinity_NN can_MD be_VB due_JJ to_TO either_CC a_DT direct_JJ alteration_NN of_IN the_DT target_NN or_CC to_TO the_DT indirect_JJ action_NN of_IN an_DT allosteric_JJ effector_NN which_WDT increases_VBZ the_DT dissociation_NN of_IN the_DT drug_NN ._SENT (_( i_NP )_) Reduction_NN of_IN the_DT target_NN affinity_NN for_IN the_DT drug_NN ._SENT |_SYM To_TO explore_VB the_DT first_JJ possibility_NN ,_, the_DT capacity_NN of_IN sparsomycin_NN to_TO inhibit_VB a_DT poly(U)-dependent_JJ polyphenylalanine_NN synthesis_NN cell-free_JJ system_NN derived_VBN from_IN S._NP sparsogenes_NNS ,_, S._NP lividans_NP SLT4_NP ,_, and_CC the_DT parental_JJ S._NP lividans_NNS 3131_CD was_VBD estimated_VBN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, all_PDT the_DT extracts_VBZ were_VBD equally_RB sensitive_JJ to_TO sparsomycin_NN ._SENT Moreover_RB ,_, ribosomes_NNS from_IN S._NP sparsogenes_NNS and_CC from_IN S._NP lividans_NNS ,_, grown_VBN either_RB in_IN the_DT absence_NN (_( sparsomycin_NN sensitive_JJ )_) or_CC in_IN the_DT presence_NN of_IN thiostrepton_NN (_( sparsomycin_NN resistant_NN )_) had_VBD a_DT similar_JJ capacity_NN to_TO bind_VB the_DT drug_NN ._SENT These_DT results_NNS indicate_VBP that_IN the_DT resistance_NN shown_VBN either_RB by_IN the_DT producer_NN or_CC by_IN the_DT resistant_JJ S._NP lividans_NNS is_VBZ not_RB due_JJ to_TO either_CC a_DT direct_JJ or_CC an_DT indirect_JJ effect_NN on_IN the_DT affinity_NN of_IN the_DT target_NN ,_, namely_RB the_DT ribosome_NN ,_, for_IN sparsomycin_NN ._SENT (_( ii_NP )_) Modification_NN of_IN the_DT drug_NN by_IN the_DT resistant_JJ cells_NNS ._SENT |_SYM To_TO test_VB whether_IN the_DT resistant_JJ cells_NNS are_VBP able_JJ to_TO inactivate_VB the_DT antibiotic_NN by_IN modifying_VBG its_PP$ structure_NN in_IN some_DT way_NN ,_, S._NP sparsogenes_NP and_CC S._NP lividans_NP SLT4_NP cells_NNS were_VBD incubated_VBN with_IN radioactive_JJ sparsomycin_NN ,_, 125I-labeled_JJ phenol-alanine-sparsomycin_NN ,_, for_IN 1_CD h._NN The_DT cells_NNS were_VBD broken_VBN afterwards_RB and_CC the_DT extracts_VBZ were_VBD centrifuged_VBN ,_, yielding_VBG a_DT supernatant_JJ and_CC a_DT pellet_NN ._SENT Both_DT fractions_NNS were_VBD treated_VBN with_IN ethyl_NN acetate_NN to_TO extract_VB the_DT drug_NN ,_, which_WDT was_VBD then_RB analyzed_VBN by_IN thin-layer_JJ chromatography_NN using_VBG different_JJ solvents_NNS ._SENT No_DT alteration_NN of_IN the_DT drug_NN mobility_NN could_MD be_VB observed_VBN in_IN any_DT of_IN the_DT cases_NNS using_VBG untreated_JJ 125I-labeled_JJ phenol-alanine-sparsomycin_NN as_IN a_DT control_NN (_( data_NNS not_RB shown_VBN )_) ._SENT (_( iii_NP )_) Accumulation_NP of_IN sparsomycin_NN by_IN the_DT cells_NNS ._SENT |_SYM A_DT possible_JJ alteration_NN in_IN sparsomycin_NN transport_NN in_IN the_DT resistant_JJ strains_NNS was_VBD checked_VBN by_IN testing_VBG the_DT capacity_NN of_IN the_DT cells_NNS to_TO accumulate_VB the_DT same_JJ radioactive_JJ derivative_NN of_IN sparsomycin_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT radioactivity_NN found_VBN in_IN S._NP sparsogenes_NNS and_CC in_IN S._NP lividans_NP SLT4_NP was_VBD considerably_RB lower_JJR than_IN that_DT found_VBN in_IN the_DT sensitive_JJ S._NP lividans_NNS 3131_CD strain_NN ._SENT In_IN order_NN to_TO characterize_VB in_IN more_JJR detail_NN the_DT different_JJ abilities_NNS to_TO accumulate_VB sparsomycin_NN of_IN the_DT resistant_JJ and_CC sensitive_JJ strains_NNS ,_, cells_NNS were_VBD fractionated_VBN and_CC the_DT capacities_NNS of_IN different_JJ fractions_NNS to_TO bind_VB radioactive_JJ drug_NN were_VBD estimated_VBN ._SENT As_IN summarized_VBN in_IN Table_NP ,_, the_DT membrane_NN fractions_NNS derived_VBN from_IN S._NP sparsogenes_NNS and_CC SLT4_NN bound_VBN more_RBR radioactive_JJ drug_NN than_IN the_DT equivalent_JJ fractions_NNS from_IN sensitive_JJ cells_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Susceptibility_NP of_IN S._NP lividans_NP Susceptibility_NP of_IN S._NP lividans_NP SLT4_NP to_TO 90_CD mug_NN (_( disk_NN 1_CD )_) and_CC 60_CD mug_NN (_( disk_NN 2_CD )_) of_IN sparsomycin_NN after_IN (_( A_NP )_) and_CC before_IN (_( B_NP )_) the_DT curing_VBG of_IN plasmid_NN pIJ702_NN containing_VBG the_DT S._NP sparsogenes_NNS DNA_NN insert_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Effect_NN of_IN antibiotics_NNS on_IN the_DT growth_NN of_IN S._NP lividans_NNS Effect_NN of_IN antibiotics_NNS on_IN the_DT growth_NN of_IN S._NP lividans_NNS parental_JJ 3131_CD and_CC SLT4_NP transformant_NN strains_NNS ._SENT (_( A_NP )_) E_NP ,_, erythromycin_NN (_( 60_CD mug_NN )_) ;_: C_NP ,_, chloramphenicol_NN (_( 50_CD mug_NN )_) ;_: S_NP ,_, sparsomycin_NN (_( 90_CD mug_NN )_) ._SENT (_( B_NP )_) T_NN ,_, tetracycline_NN (_( 30_CD mug_NN )_) ;_: L_NP ,_, lincomycin_NN (_( 60_CD mug_NN )_) ;_: P_NN ,_, puromycin_NN (_( 150_CD mug_NN )_) ._SENT The_DT antibiotics_NNS were_VBD placed_VBN on_IN filter_NN paper_NN disks_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Subcloning_NP of_IN the_DT S._NP sparsogenes_NNS Subcloning_VBG of_IN the_DT S._NP sparsogenes_NNS DNA_NN insert_NN ._SENT Different_JJ fragments_NNS of_IN the_DT original_JJ insert_NN in_IN the_DT plasmids_NNS isolated_VBN from_IN S._NP lividans_NP SLT4_NP were_VBD subcloned_VBN on_IN pJI702_NN as_IN indicated_VBN and_CC tested_VBN for_IN their_PP$ capacity_NN to_TO induce_VB sparsomycin_NN resistance_NN in_IN wild-type_JJ S._NP lividans_NNS 1326_CD ._SENT FIG._NN 4_CD ._SENT |_SYM Analysis_NN of_IN the_DT nucleotide_NN sequence_NN of_IN the_DT 3_CD ._SENT Analysis_NN of_IN the_DT nucleotide_NN sequence_NN of_IN the_DT 3.9-kbp_JJ fragment_NN ._SENT Analysis_NN of_IN G+C_NP content_NN identified_VBD three_CD putative_JJ ORFs_NNS in_IN the_DT sequence_NN ,_, marked_JJ srd_NN ,_, moxR_NN ,_, and_CC tmp_NN ._SENT The_DT region_NN included_VBD in_IN the_DT different_JJ inserts_NNS in_IN Fig._NN is_VBZ indicated_VBN at_IN the_DT bottom_NN ._SENT A_DT vertical_JJ line_NN marks_VBZ the_DT starting_VBG point_NN of_IN the_DT S._NP sparsogenes_NNS DNA_NN ._SENT FIG._NN 5_CD ._SENT |_SYM Nucleotide_NN and_CC deduced_VBN amino_NN acid_NN sequences_NNS of_IN the_DT srd_NP ORF_NP ._SENT Nucleotide_NN and_CC deduced_VBN amino_NN acid_NN sequences_NNS of_IN the_DT srd_NP ORF_NP ._SENT FIG._NN 6_CD ._SENT |_SYM Sparsomycin_NP inhibition_NN of_IN polyphenylalanine_JJ synthesis_NN in_IN cell_NN extracts_VBZ from_IN S._NP sparsogenes_NP Sparsomycin_NP inhibition_NN of_IN polyphenylalanine_JJ synthesis_NN in_IN cell_NN extracts_VBZ from_IN S._NP sparsogenes_NNS ,_, wild-type_JJ S._NP lividans_NNS ,_, and_CC S._NP lividans_NP SLT4_NP ._SENT Polymerizing_VBG activity_NN was_VBD tested_VBN according_VBG to_TO standard_JJ methods_NNS in_IN the_DT presence_NN of_IN the_DT indicated_JJ concentrations_NNS of_IN sparsomycin_NN ._SENT Activity_NN is_VBZ shown_VBN as_IN the_DT percentage_NN of_IN the_DT samples_NNS tested_VBN in_IN the_DT absence_NN of_IN drug_NN ._SENT FIG._NN 7_CD ._SENT |_SYM Binding_NP of_IN 125I-labeled_JJ phenol-sparsomycin_NN to_TO ribosomes_NNS from_IN resistant_JJ and_CC sensitive_JJ strains_NNS ._SENT Binding_VBG of_IN 125I-labeled_JJ phenol-sparsomycin_NN to_TO ribosomes_NNS from_IN resistant_JJ and_CC sensitive_JJ strains_NNS ._SENT Ribosomes_NNS (_( 50_CD pmol_NN )_) from_IN S._NP sparsogenes_NP and_CC S._NP lividans_NNS 3131_CD grown_VBN in_IN the_DT absence_NN or_CC in_IN the_DT presence_NN of_IN 0.5_CD mg_NN of_IN thiostrepton/ml_NN were_VBD incubated_VBN with_IN increasing_VBG amounts_NNS of_IN 0.1_CD muM_NN 125_CD I-labeled_JJ phenol-sparsomycin_NNS (_( 103_CD cpm/pmol_NN )_) ,_, and_CC the_DT amount_NN of_IN bound_JJ antibiotic_NN was_VBD estimated_VBN by_IN filtration_NN ._SENT FIG._NN 8_CD ._SENT |_SYM Accumulation_NP of_IN radioactive_JJ sparsomycin_NN by_IN sensitive_JJ and_CC resistant_JJ Streptomyces_NP cells_NNS ._SENT Cells_NNS from_IN S._NP sparsogenes_NP Accumulation_NP of_IN radioactive_JJ sparsomycin_NN by_IN sensitive_JJ and_CC resistant_JJ Streptomyces_NP cells_NNS ._SENT Cells_NNS from_IN S._NP sparsogenes_NNS ,_, S._NP lividans_NP SLT4_NP (_( *_SYM )_) ,_, and_CC S._NP lividans_NNS 3131_CD grown_VBN to_TO mid-exponential_JJ phase_NN were_VBD collected_VBN ,_, washed_VBN ,_, and_CC resuspended_JJ in_IN binding_VBG buffer_NN to_TO an_DT A550_NP of_IN 5.0_CD ._SENT A_DT total_NN of_IN 100,000_CD cpm_NN of_IN 125I-labeled_JJ phenol-sparsomycin_NN was_VBD added_VBN and_CC the_DT samples_NNS were_VBD incubated_VBN at_IN 30C_JJ ._SENT Cells_NNS were_VBD afterwards_RB filtered_VBN through_IN glass_NN fiber_NN filters_NNS and_CC washed_VBN with_IN binding_JJ buffer_NN ,_, and_CC the_DT radioactivity_NN was_VBD estimated_VBN by_IN scintillation_NN counting_NN ._SENT TABLE_NN 1_CD |_SYM Binding_NP of_IN 125I-phenol-alanine-sparsomycin_NP by_IN different_JJ cellular_JJ fractions_NNS The_DT results_NNS from_IN the_DT sparsomycin_NN producer_NN S._NP sparsogenes_NNS ,_, as_RB well_RB as_IN from_IN the_DT resistant_JJ S._NP lividans_NNS SLT4_NP expressing_VBG a_DT resistant_JJ genetic_JJ determinant_NN from_IN the_DT producer_NN ,_, clearly_RB show_VBP that_IN the_DT ribosomes_NNS from_IN both_DT types_NNS of_IN strains_NNS bind_VBP the_DT drug_NN to_TO a_DT similar_JJ extent_NN ._SENT These_DT data_NNS indicate_VBP that_IN the_DT resistance_NN mechanism_NN working_VBG in_IN both_DT strains_NNS does_VBZ not_RB involve_VB modification_NN of_IN the_DT drug_NN target_NN ,_, the_DT ribosomal_JJ peptidyl_NN transferase_NN center_NN ._SENT Similarly_RB ,_, since_IN the_DT drug_NN inhibits_VBZ the_DT in_IN vitro_NN protein-synthesizing_VBG activity_NN of_IN extracts_VBZ derived_VBN from_IN the_DT resistant_JJ and_CC sensitive_JJ strains_NNS equally_RB ,_, the_DT action_NN of_IN an_DT allosteric_JJ effector_NN inducing_VBG a_DT rapid_JJ dissociation_NN of_IN sparsomycin_NN ,_, like_IN the_DT Tet(M)_NP class_NN of_IN proteins_NNS in_IN tetracycline_NN resistance_NN ,_, can_MD also_RB be_VB excluded_VBN ._SENT Sparsomycin_NN is_VBZ ,_, indeed_RB ,_, a_DT very_RB efficient_JJ inhibitor_NN of_IN the_DT peptide_NN bond_NN formation_NN in_IN the_DT Bacteria_NP as_RB well_RB as_IN in_IN Archaea_NP and_CC in_IN Eucarya_NP ._SENT Affinity_NN labeling_VBG data_NNS have_VBP shown_VBN that_IN the_DT antibiotic_NN seems_VBZ to_TO bind_VB to_TO nucleotide_NN A2602_NN in_IN the_DT 23S_JJ rRNA_NN peptidyl_NN transferase_NN domain_NN ,_, which_WDT is_VBZ very_RB close_JJ to_TO the_DT active_JJ center_NN ,_, as_RB revealed_VBN by_IN the_DT 2.4_CD A_DT three-dimensional_JJ structure_NN of_IN the_DT 50S_JJ ribosomal_JJ subunit_NN recently_RB reported_VBD ._SENT Sparsomycin_NN is_VBZ ,_, therefore_RB ,_, interacting_VBG at_IN a_DT very_RB critical_JJ site_NN of_IN the_DT ribosome_NN which_WDT ,_, apparently_RB ,_, evolution_NN has_VBZ not_RB been_VBN able_JJ to_TO modify_VB in_IN order_NN to_TO produce_VB a_DT sparsomycin-resistant_JJ ribosome_NN ._SENT In_IN fact_NN ,_, the_DT putative_JJ drug_NN binding_VBG site_NN ,_, A2602_NP ,_, is_VBZ a_DT universally_RB conserved_VBN nucleotide_NN ,_, which_WDT underlines_VBZ its_PP$ functional_JJ importance_NN and_CC accounts_NNS for_IN the_DT broad_JJ range_NN of_IN organisms_NNS sensitive_JJ to_TO the_DT drug_NN ._SENT S._NP sparsogenes_NNS does_VBZ not_RB seem_VB to_TO resist_VB exogenous_JJ sparsomycin_NN by_IN modifying_VBG the_DT drug_NN either_CC ,_, since_IN radioactive_JJ drug_NN incubated_VBN with_IN the_DT resistant_JJ cells_NNS was_VBD chromatographically_RB indistinguishable_JJ from_IN the_DT untreated_JJ controls_NNS ._SENT Since_IN the_DT target_NN is_VBZ sensitive_JJ to_TO sparsomycin_NN and_CC the_DT drug_NN is_VBZ not_RB inactivated_VBN by_IN modification_NN ,_, the_DT resistance_NN mechanism_NN in_IN the_DT resistant_JJ strains_NNS must_MD lay_VB at_IN the_DT level_NN of_IN the_DT permeability_NN barrier_NN ._SENT Thus_RB ,_, it_PP has_VBZ been_VBN found_VBN that_IN S._NP sparsogenes_NNS accumulates_VBZ considerably_RB less_JJR drug_NN than_IN the_DT sensitive_JJ S._NP lividans_NNS cells_NNS when_WRB incubated_VBN in_IN the_DT presence_NN of_IN radioactive_JJ sparsomycin_NN ,_, suggesting_VBG that_DT resistance_NN probably_RB results_VBZ from_IN differences_NNS in_IN the_DT cell_NN permeability_NN ._SENT It_PP was_VBD possible_JJ to_TO transform_VB sparsomycin_NN resistance_NN in_IN sensitive_JJ S._NP lividans_NNS cells_NNS by_IN using_VBG an_DT S._NP sparsogenes_NNS DNA_NN library_NN ._SENT The_DT biochemical_JJ characteristics_NNS of_IN the_DT resistance_NN phenotype_NN in_IN the_DT transformant_JJ S._NP lividans_NNS SLT4_NP cells_NNS are_VBP similar_JJ to_TO those_DT found_VBN in_IN the_DT producer_NN ,_, namely_RB ,_, sparsomycin_NN susceptibility_NN of_IN the_DT translation_NN machinery_NN ,_, inability_NN to_TO modify_VB the_DT drug_NN ,_, and_CC reduced_VBD cellular_JJ accumulation_NN of_IN antibiotic_NN ._SENT These_DT results_NNS suggest_VBP ,_, therefore_RB ,_, that_DT resistance_NN to_TO sparsomycin_NN in_IN the_DT producer_NN might_MD be_VB associated_VBN with_IN an_DT alteration_NN in_IN the_DT transport_NN process_NN ._SENT The_DT fact_NN that_IN the_DT sparsomycin_NN resistance_NN determinant_NN also_RB affects_VBZ the_DT sensitivity_NN of_IN the_DT cells_NNS to_TO several_JJ other_JJ inhibitors_NNS supports_VBZ an_DT effect_NN at_IN the_DT level_NN of_IN permeability_NN ,_, although_IN this_DT hypothesis_NN must_MD be_VB experimentally_RB confirmed_VBN ._SENT An_DT increasing_VBG number_NN of_IN antibiotic-producing_NN organisms_NNS have_VBP been_VBN shown_VBN to_TO contain_VB active_JJ transport_NN systems_NNS that_WDT efficiently_RB export_VBP the_DT antibiotic_JJ molecules_NNS to_TO the_DT exterior_NN ._SENT The_DT mechanisms_NNS can_MD be_VB divided_VBN into_IN two_CD classes_NNS ._SENT One_CD of_IN them_PP is_VBZ connected_VBN to_TO proton-driven_JJ membrane_NN electrochemical_JJ gradients_NNS and_CC involves_VBZ mdr-type_NN proteins_NNS ._SENT The_DT other_JJ one_CD is_VBZ based_VBN on_IN the_DT ABC_NP transporter_NN system_NN ,_, which_WDT couples_VBZ antibiotic_JJ transport_NN to_TO ATP_NP hydrolysis_NN ._SENT The_DT S._NP sparsogenes_NNS genetic_JJ determinant_NN responsible_JJ for_IN sparsomycin_NN resistance_NN in_IN S._NP lividans_NP SLT4_NP can_MD be_VB associated_VBN with_IN srd_NN ,_, an_DT ORF_NP that_WDT encodes_VBZ a_DT 600-amino-acid_JJ polypeptide_NN ._SENT However_RB ,_, no_DT significant_JJ homology_NN of_IN sdr_NN has_VBZ been_VBN found_VBN to_TO any_DT sequence_NN in_IN either_DT DNA_NN or_CC protein_NN data_NNS banks_NNS ,_, suggesting_VBG that_IN the_DT mechanism_NN involved_VBN in_IN sparsomycin_NN transport_NN is_VBZ not_RB related_VBN to_TO either_DT of_IN the_DT two_CD systems_NNS so_RB far_RB described_VBN ._SENT Nevertheless_RB ,_, since_IN S._NP lividans_NP SLT4_NP accumulates_VBZ sparsomycin_NN at_IN a_DT somewhat_RB higher_JJR level_NN than_IN the_DT producer_NN ,_, it_PP cannot_MD be_VB ruled_VBN out_RP that_IN the_DT cloned_VBN determinant_NN is_VBZ only_RB a_DT part_NN of_IN the_DT mechanism_NN working_VBG in_IN the_DT producer_NN ._SENT There_EX is_VBZ a_DT novel_JJ drug-binding-protein-dependent_JJ export_NN system_NN that_WDT has_VBZ been_VBN described_VBN in_IN Streptomyces_NP lavendulae_NNS ,_, in_IN which_WDT two_CD components_NNS ,_, mct_NN ,_, a_DT putative_JJ mitomycin_NN transport_NN gene_NN ,_, and_CC mrd_NN ,_, encoding_VBG a_DT mitomycin-binding_JJ protein_NN ,_, work_VB synergistically_RB to_TO confer_VB resistance_NN to_TO mitomycin_NN in_IN the_DT producer_NN strain_NN ._SENT Perhaps_RB srd_NN is_VBZ only_RB one_CD part_NN of_IN a_DT transport_NN system_NN present_NN in_IN S._NP sparsogenes_NNS ._SENT Interestingly_RB ,_, a_DT membrane_NN fraction_NN of_IN the_DT resistant_JJ strain_NN ,_, S._NP lividans_NP SLT4_NP ,_, binds_VBZ more_RBR radioactive_JJ sparsomycin_NN than_IN the_DT equivalent_JJ fraction_NN from_IN sensitive_JJ S._NP lividans_NNS ,_, suggesting_VBG that_IN srd_NN might_MD encode_VB a_DT sparsomycin-binding_JJ protein_NN ,_, as_IN mrd_NN does_VBZ in_IN the_DT case_NN of_IN mitomycin_NN ._SENT Srd_NP ,_, in_IN spite_NN of_IN not_RB being_VBG a_DT typical_JJ membrane_NN protein_NN ,_, might_MD be_VB an_DT accessory_JJ component_NN of_IN the_DT transport_NN mechanism_NN required_VBN for_IN optimal_JJ efficiency_NN ._SENT In_IN any_DT case_NN ,_, these_DT results_NNS must_MD be_VB considered_VBN as_IN preliminary_JJ ,_, and_CC further_JJR studies_NNS using_VBG the_DT recombinant_JJ protein_NN will_MD be_VB required_VBN to_TO locate_VB the_DT protein_NN in_IN the_DT cell_NN and_CC to_TO obtain_VB further_JJR insight_NN into_IN the_DT real_JJ transport_NN mechanism_NN involved_VBN in_IN sparsomycin_NN resistance_NN ._SENT 